Gelsolin (BioAegis Therapeutics)

N/A

Report date: 2025/06/20 14:21:15

Base Information

Drug NameGelsolin (BioAegis Therapeutics)
Drug Alias Namerh gelsolinhu r-P gelsolinRecombinant human plasma gelsolin (BioAegis Therapeutics)Gelsolin recombinant (BioAegis Therapeutics)Solinex +[7] 
ClassificationBiologics > Protein drugs
Mechanisms of ActionActin inhibitors
TargetsActin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaBurns +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Brigham and Women's Hospital
China Registration ClassN/A

Develop Information

Active CompaniesBioAegis Therapeutics IncUniversity Of Maryland
Inactive CompaniesCritical Biologics Corporation
Active IndicationsCoronavirus Disease 2019 (COVID-19)Decompression SicknessDiabetes Mellitus, Type 2 +[5] 
Inactive IndicationsCommunity Acquired PneumoniaBurnsWounds and Injuries

Other Information

ATC CodeN/A
Related LinksN/A